Investment Rating - The industry rating is "Recommended" [3] Core Insights - The report highlights the ongoing decline in pork prices, with the average price of live pigs at 12.64 CNY/kg, down 3.05% week-on-week, indicating a supply surplus in the market. However, upcoming festivals are expected to boost consumption and potentially stabilize prices [2][13] - The report emphasizes the importance of improving grain yield through advanced agricultural practices and technology, particularly in the context of food security and the promotion of genetically modified crops [1][12] Summary by Sections Planting Industry Chain - The Ministry of Agriculture and Rural Affairs is focusing on enhancing grain yields through a comprehensive approach tailored to specific crops and regions. This includes promoting high-performance agricultural machinery and addressing storage issues in different regions [1][12] - Companies like Beidahuang and Suqian Agricultural Development are expected to benefit from these initiatives, along with seed companies such as Dabeinong and Longping High-Tech [1][12] Swine Farming - The current average price of live pigs is 12.64 CNY/kg, reflecting a significant decrease due to oversupply. A meeting was held to discuss reducing the breeding sow population by approximately 1 million to stabilize prices [2][13] - The report suggests that the swine industry will focus on quality improvement and efficiency, with a gradual elimination of outdated production capacity. Companies like Muyuan Foods and Wen's Foodstuffs are highlighted as key players to watch [2][5][13] Key Agricultural Product Data Tracking - Corn: The average price is 2360.47 CNY/ton, down 0.10% week-on-week [26] - Wheat: The average price is 2434.39 CNY/ton, up 0.23% week-on-week [29] - Soybeans: The average price is 4050.42 CNY/ton, up 0.17% week-on-week [38] - Cotton: The average price is 15090.00 CNY/ton, down 0.89% week-on-week [46] Feed and Vitamin Prices - The average price of pig feed is 2.68 CNY/kg, with no change week-on-week. Vitamin E prices have decreased by 7.84% to 51.70 CNY/kg [52][63]

Core Viewpoint - The animal health sector experienced a rise of 1.59% on September 26, with Bio-Pharmaceuticals leading the gains, while the overall market indices, Shanghai Composite and Shenzhen Component, saw declines of 0.65% and 1.76% respectively [1] Group 1: Market Performance - The animal health sector's individual stock performance showed significant variations, with Bio-Pharmaceuticals closing at 9.34, up by 7.23%, and a trading volume of 1.0367 million shares, resulting in a turnover of 973 million yuan [1] - Other notable performers included Huisheng Biological at 20.68, up by 1.87%, and Ruipu Biological at 20.93, up by 1.60% [1] Group 2: Capital Flow - The animal health sector saw a net inflow of 86.5157 million yuan from institutional investors, while retail investors experienced a net outflow of 44.7995 million yuan [2] - The capital flow data indicates that major stocks like Bio-Pharmaceuticals had a net inflow of 12.63% from institutional investors, despite a significant outflow from retail and speculative investors [3]

Core Points - The stock of Jinyu Biological Technology Co., Ltd. increased by 5.05% on September 26, reaching a price of 9.15 yuan per share, with a trading volume of 148 million yuan and a turnover rate of 1.50%, resulting in a total market capitalization of 10.172 billion yuan [1] - The company, established on March 13, 1993, and listed on January 15, 1999, primarily engages in the research, production, and sales of veterinary biological products, with its main business revenue composition being 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Fund Holdings - According to data, one fund under E Fund has a significant holding in Jinyu Biological. The E Fund CSI Modern Agriculture Theme ETF (562900) held 219,500 shares in the second quarter, accounting for 2.53% of the fund's net value, ranking as the ninth largest holding. The estimated floating profit for today is approximately 96,600 yuan [2] - The E Fund CSI Modern Agriculture Theme ETF (562900) was established on December 2, 2021, with a latest scale of 69.4581 million yuan. Year-to-date returns are 13.07%, ranking 3,388 out of 4,220 in its category; the one-year return is 26.63%, ranking 3,109 out of 3,824; and since inception, it has incurred a loss of 18.59% [2] Fund Manager Information - The fund manager of the E Fund CSI Modern Agriculture Theme ETF (562900) is Song Zhaoxian, who has been in the position for 5 years and 23 days. The total asset scale of the fund is 28.905 billion yuan, with the best fund return during his tenure being 74.37% and the worst being -31.03% [3]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown a significant increase of 30.31% year-to-date, despite a recent decline of 1.11% over the past five trading days [1][2] Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1] - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Financial Performance - For the first half of 2025, the company reported an operating income of 620 million yuan, reflecting a year-on-year growth of 1.28%. However, the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2] - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% from the previous period [2] - The top ten circulating shareholders include notable ETFs, with the Guotai Zhongzheng Livestock Breeding ETF holding 15.95 million shares, an increase of 648,300 shares from the previous period [3]

Market Overview - On September 25, the animal health sector declined by 1.62% compared to the previous trading day, with the leading stock, Driveline, experiencing a drop of 4.04% [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - The following stocks in the animal health sector showed notable declines: - Driveline (Code: 838275) closed at 9.50, down 4.04% with a trading volume of 19,300 lots [1] - Shunlian Bio (Code: 688098) closed at 10.43, down 3.43% with a trading volume of 76,300 lots [1] - Yongshun Bio (Code: 839729) closed at 9.74, down 2.89% with a trading volume of 20,800 lots [1] - Other notable declines include *ST Green Health (Code: 002868) down 2.39% and Shoufeng Holdings (Code: 002141) down 2.33% [1] Capital Flow - The animal health sector saw a net outflow of 113 million yuan from institutional investors, while retail investors experienced a net inflow of 61.16 million yuan [1] - The following stocks had significant capital flow: - Zhongmu Co. (Code: 600195) had a net inflow of 986,800 yuan from institutional investors [2] - Pulaike (Code: 603566) saw a net inflow of 764,200 yuan from retail investors [2] - *ST Green Health (Code: 002868) experienced a net outflow of 6.71 million yuan from institutional investors [2]

Market Overview - On September 19, the animal health sector declined by 0.26% compared to the previous trading day, with the driving force leading the decline [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable stock movements included: - *ST Lvkang (002868): Closed at 27.56, up 4.99% with a trading volume of 38,500 shares and a turnover of 105 million yuan [1] - Kexin Biological (688526): Closed at 18.08, up 0.39% with a trading volume of 22,700 shares and a turnover of 40.94 million yuan [1] - Driving Force (838275): Closed at 10.50, down 4.11% with a trading volume of 21,200 shares and a turnover of 22.63 million yuan [2] Capital Flow - The animal health sector experienced a net outflow of 91.4 million yuan from institutional investors, while retail investors saw a net inflow of 70.15 million yuan [2] - The capital flow for individual stocks showed: - RuiPu Biological (300119): Net inflow of 16.56 million yuan from institutional investors, but a net outflow of 21.57 million yuan from retail investors [3] - *ST Lvkang (002868): Net inflow of 6.13 million yuan from institutional investors, with a net outflow of 4.21 million yuan from retail investors [3]

Market Overview - On September 18, the animal health sector declined by 0.77% compared to the previous trading day, with Huisheng Biological leading the decline [1] - The Shanghai Composite Index closed at 3831.66, down 1.15%, while the Shenzhen Component Index closed at 13075.66, down 1.06% [1] Stock Performance - The following stocks in the animal health sector showed notable performance: - *ST Lvkang (002868): Closed at 26.25, up 5.00% with a trading volume of 3433 lots [1] - Shengbi Biological (600201): Closed at 66.8, down 2.39% with a trading volume of 55.74 million [1] - Ruipu Biological (300119): Closed at 22.06, unchanged with a trading volume of 111.3 million [1] - Other stocks such as Jinhai Biological (002688) and Shunlian Biological (688098) also experienced declines of 1.98% and 2.02% respectively [1][2] Capital Flow - The animal health sector experienced a net outflow of 126 million yuan from institutional investors, while retail investors saw a net inflow of 92.38 million yuan [2] - The following stocks had significant capital flow: - Ruipu Biological: Net inflow of 12.35 million yuan from institutional investors [3] - *ST Lvkang: Net outflow of 3.83 million yuan from institutional investors [3] - Jinhai Biological: Net outflow of 25.51 million yuan from institutional investors [3]

Group 1 - The company held a half-year performance briefing on September 17, 2025, via the Shanghai Stock Exchange Roadshow Center [1] - Key executives, including the chairman and president, participated in the briefing and engaged with investors through online interaction [1] - The company is actively promoting a small-scale rapid refinancing through a simplified procedure for targeted issuance of shares, with a financing cap of RMB 300 million [2][5] Group 2 - The company received authorization from its shareholders to issue shares not exceeding 20% of the net assets as of the end of the previous year, with the authorization valid until the next annual shareholders' meeting [2] - The company is focusing on enhancing its core business and exploring new opportunities in the health and judicial IVD sectors, driven by high-tech development [5][7] - The company is implementing measures to strengthen internal controls over accounts receivable and reduce bad debt risks, including customer credit assessments and regular reconciliations [9][10]

Group 1 - The Chinese beauty products industry is accelerating its "going global" strategy, with exports of cosmetics and personal care products expected to reach 51.2 billion RMB in 2024, a year-on-year increase of 11.9% [1] - Incorporating Chinese culture into brand building is seen as an effective strategy for establishing brand recognition in overseas markets, with companies like Plant Doctor Group using traditional Chinese medicinal ingredients to attract consumers [1][2] - The rise of Chinese cultural influence is enhancing the appeal of domestic beauty brands in international markets, as brands that integrate cultural elements into their narratives can build unique recognition [2][3] Group 2 - Localized design strategies are crucial for Chinese beauty brands to succeed in diverse international markets, as consumer preferences vary significantly across regions [4][5] - Companies like Orange Group are focusing on understanding overseas market preferences and adapting their products accordingly, including developing new shades and formulations to meet local needs [4][5] - Establishing local teams and R&D centers abroad helps brands better align with market demands and regulatory standards, enhancing consumer trust and product freshness [5][6] Group 3 - Continuous investment in technological innovation is strengthening the competitive edge of Chinese beauty products in the global market, with companies developing proprietary technologies and establishing comprehensive supply chains [6][7] - The industry is witnessing a shift towards technology-driven growth, with brands increasingly focusing on R&D to create effective products that meet consumer needs [7][8] - The next 3 to 5 years are expected to see an intensified effort from Chinese beauty brands to expand internationally, particularly in emerging markets, facilitated by the growth of cross-border e-commerce [8]

Market Overview - On September 16, the animal health sector declined by 0.41%, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Stock Performance - Key stocks in the animal health sector showed mixed performance, with the following notable movements: - Xianfeng Holdings (002141) increased by 2.27% to close at 4.06 [1] - Haili Biological (603718) rose by 1.27% to 7.17 [1] - *ST Lvkang (002868) fell by 4.34% to 23.81, leading the decline [2] - The trading volume and turnover for selected stocks were significant, with Xianfeng Holdings achieving a turnover of 1.02 billion [1] Capital Flow Analysis - The animal health sector experienced a net outflow of 15.97 million from institutional investors, while retail investors saw a net inflow of 11.29 million [2][3] - Notable capital flows included: - Biological Shares (600201) had a net inflow of 12.28 million from institutional investors [3] - *ST Lvkang (002868) saw a net outflow of 2.89 million from institutional investors [3] - Retail investors contributed positively to several stocks, including a net inflow of 12.59 million into Shenyuan Biological (688098) [3]